What is the 13F Pro Quality Score for INO?

13F Pro ranks INOVIO PHARMACEUTICALS, INC. (INO) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View INO's current score at https://13fpro.ai/company/INO (free sign-up required for the full ranking).

Which hedge funds own the most INO stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of INO include FMR, Jupiter Topco, VANGUARD CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/INO as soon as new 13F filings post.

Where does 13F Pro source INO data?

All INOVIO PHARMACEUTICALS, INC. fundamentals and ownership data come directly from SEC EDGAR. INOVIO PHARMACEUTICALS, INC. files with the SEC under CIK 1055726. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is INO in?

INOVIO PHARMACEUTICALS, INC. (INO) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is INO research updated on 13F Pro?

INO's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

INOVIO PHARMACEUTICALS, INC.(INO)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1055726 INO stock profile & AI dashboard →

13F Pro Quality Score

13.5/100

Rank #2,875 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why INO Scores 14/100

exact factor attribution · 2026-09-11

INO's composite is held back by free cash flow and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Earnings growth

-1.0 pts

30th pct

Institutional flow

-2.2 pts

5th pct

Shareholder dilution

-2.5 pts

1th pct

Scale

-3.0 pts

30th pct

Revenue growth

-4.0 pts

30th pct

Earnings quality

-4.2 pts

8th pct

Capital efficiency

-4.7 pts

4th pct

Profitability

-7.4 pts

0th pct

Free cash flow

-7.5 pts

0th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

INO Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for INOVIO PHARMACEUTICALS, INC. (INO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores INO at 13.5/100 on a 32-signal composite quality model, placing it at rank #2,875 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), INOVIO PHARMACEUTICALS, INC. reports net income of $-6.0M, free cash flow of $-18.0M. Top institutional holders of INO by reported 13-F value include FMR, Jupiter Topco, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. INO trades on the Nasdaq exchange and files with the SEC under CIK 1055726. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate INO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for INOVIO PHARMACEUTICALS, INC. directly from SEC EDGAR. INOVIO PHARMACEUTICALS, INC.'s 13F Pro composite quality score has ranged between 2 and 24 since 2024, currently 13.5 — a declining long-term trajectory across 30 quarterly and live scoring snapshots.

✦

Fun facts about INOVIO PHARMACEUTICALS, INC.

Quirks, history, and lore behind INO — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in Pennsylvania · focused on infectious diseases and cancer.
2
The Numbers
A small-cap with minimal product revenue — it runs largely on grants, partnerships, and capital raises, as most clinical-stage biotechs do.
3
The History
Founded in the late 1970s, it spent decades pioneering a novel approach to delivering genetic medicine directly into cells using a handheld electroporation device.
4
The Secret
Its core platform skips viruses entirely — instead of a viral vector, it uses electrical pulses to push DNA plasmids into the body's own cells to trigger an immune response.
5
The Lore
During the COVID-19 pandemic, its DNA-based vaccine candidate drew enormous buzz and a stock price surge — before larger mRNA rivals ultimately dominated the race.
6
The Giveaway
Its signature handheld CELLECTRA device and a pipeline built almost entirely on DNA medicine make this Pennsylvania biotech the odd one out in a world gone mRNA.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$0.00

Net Income

Q2 2026

$-6.0M

Free Cash Flow

Q2 2026

$-18.0M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-70.0% YoY

$65.3KFY 2025

FY22 $10.3MFY23 $832.0KFY24 $217.8KFY25 $65.3K

Net Income

+20.8% YoY

$-84.9MFY 2025

FY22 $-279.8MFY23 $-135.1MFY24 $-107.3MFY25 $-84.9M

Operating Income

+22.8% YoY

$-86.8MFY 2025

FY22 $-267.6MFY23 $-143.9MFY24 $-112.4MFY25 $-86.8M

EPS (Diluted)

+54.2% YoY

$-1.81FY 2025

FY22 $-14.07FY23 $-6.09FY24 $-3.95FY25 $-1.81

Total Assets

-34.4% YoY

$74.3MFY 2025

FY22 $348.5MFY23 $171.0MFY24 $113.2MFY25 $74.3M

Op. Cash Flow

+14.8% YoY

$-88.6MFY 2025

FY22 $-216.2MFY23 $-124.4MFY24 $-104.1MFY25 $-88.6M

Free Cash Flow

+15.0% YoY

$-88.9MFY 2025

FY22 $-217.2MFY23 $-124.7MFY24 $-104.6MFY25 $-88.9M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$65.3K -70.0%	$217.8K -73.8%	$832.0K -91.9%	$10.3M +478.2%	$1.8M -76.1%	$7.4M
Net Income	$-84.9M +20.8%	$-107.3M +20.6%	$-135.1M +51.7%	$-279.8M +7.9%	$-303.7M -82.5%	$-166.4M
Operating Income	$-86.8M +22.8%	$-112.4M +21.9%	$-143.9M +46.2%	$-267.6M +11.2%	$-301.2M -142.8%	$-124.1M
EPS (Diluted)	$-1.81 +54.2%	$-3.95 +35.1%	$-6.09 +56.7%	$-14.07 +19.4%	$-17.45 -1530.8%	$-1.07
Total Assets	$74.3M -34.4%	$113.2M -33.8%	$171.0M -51.0%	$348.5M -29.7%	$495.9M -8.1%	$539.8M
Operating Cash Flow	$-88.6M +14.8%	$-104.1M +16.3%	$-124.4M +42.5%	$-216.2M -0.2%	$-215.7M -21.2%	$-178.0M
Free Cash Flow	$-88.9M +15.0%	$-104.6M +16.1%	$-124.7M +42.6%	$-217.2M -0.1%	$-216.9M -20.9%	$-179.5M

Get alerted when INO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for INOVIO PHARMACEUTICALS, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of INO

FMR LLC
$9.3M8,454,797 sh
Jupiter Topco LLC
$5.7M5,171,053 sh
VANGUARD CAPITAL MANAGEMENT LLC
$4.0M3,650,562 sh
Boxer Capital Management, LLC
$3.1M2,844,994 sh
ADAR1 Capital Management, LLC
$2.4M2,143,910 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$1.7M1,520,400 sh
D. E. Shaw & Co., Inc.
$1.5M1,351,656 sh
TWO SIGMA INVESTMENTS, LP
$1.4M1,239,778 sh
Eversept Partners, LP
$1.1M1,035,360 sh
GEODE CAPITAL MANAGEMENT, LLC
$883.7K802,751 sh

Fund	Value	Shares
FMR LLC	$9.3M	8,454,797
Jupiter Topco LLC	$5.7M	5,171,053
VANGUARD CAPITAL MANAGEMENT LLC	$4.0M	3,650,562
Boxer Capital Management, LLC	$3.1M	2,844,994
ADAR1 Capital Management, LLC	$2.4M	2,143,910
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$1.7M	1,520,400
D. E. Shaw & Co., Inc.	$1.5M	1,351,656
TWO SIGMA INVESTMENTS, LP	$1.4M	1,239,778
Eversept Partners, LP	$1.1M	1,035,360
GEODE CAPITAL MANAGEMENT, LLC	$883.7K	802,751

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put INO on your watchlist

Track score changes the day INOVIO PHARMACEUTICALS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is INO a good stock to buy?

13F Pro's AI-powered analysis of INOVIO PHARMACEUTICALS, INC. (INO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for INO are available on the INO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. INO is classified as a small company.

Which hedge funds own INO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling INO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of INOVIO PHARMACEUTICALS, INC.'s investment landscape.